About 33 results found for searched term "99-50-3" (0.087 seconds)
Cat.No. | Name | Target |
---|---|---|
M11202 | Protocatechuic acid | Metabolite/Endogenous Metabolite |
3,4-Dihydroxybenzoic acid, Protocatechuate | ||
Protocatechuic acid is a natural polyphenol that has a neuroprotective effect. | ||
M11483 | A 438079 | P2 Receptor |
A 438079 is A potent, selective P2X7 receptor antagonist with A pIC50 of 6.9. | ||
M29081 | Bomedemstat | Histone demethylase |
IMG-7289 | ||
Bomedemstat (IMG-7289) is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis. | ||
M1989 | CHIR-99021 HCl | GSK-3 |
Laduviglusib hydrochloride; CHIR-99021 hydrochloride | ||
CHIR-99021 HCl (Laduviglusib; CT99021) is a hydrochloride of CHIR-99021, with IC50 of 10 nM and 6.7 nM for GSK-3α and GSK-3β, respectively. | ||
M2584 | MDL-29951 | GluR |
MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo with IC50 value of 0.14 mM ([3H]glycine binding). | ||
M2913 | Palbociclib Isethionate | CDK |
PD 0332991 isethionate | ||
Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 2/3. | ||
M2927 | PF-04880594 | Raf |
PF-04880594 is a RAF inhibitor for BRAF/BRAFV599E and c-RAF with IC50 of 0.19 nM/0.13 nM and 0.39 nM, >100-fold selectivity over CSNK1, JNK2/3 and p38. | ||
M3668 | GDC-0994 | ERK |
Ravoxertinib | ||
Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with IC50 of 6.1 nM and 3.1 nM against ERK1 and ERK2, respectively. | ||
M5123 | Y-39983 dihydrochloride | ROCK |
Y-33075 dihydrochloride | ||
Y-39983 (Y-33075) dihydrochloride is a selective ROCK inhibitor with an IC50 of 3.6 nM, derived from Y-27632, inhibited ROCK more potently than Y-27632. | ||
M5233 | Osilodrostat | Mineralocorticoid Receptor |
LCI699 | ||
Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. | ||
M5253 | BLU-9931 | FGFR |
BLU9931 | ||
BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively. | ||
M5827 | Oclacitinib maleate | JAK |
PF-03394197 | ||
Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, which did not inhibit a panel of 38 non-JAK kinases. | ||
M6474 | AY 9944 | Others |
AY 9944 dihydrochloride | ||
AY 9944 is a specific cholesterol biosynthesis inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme with an IC50 of 13 nM. | ||
M6594 | CHIR 99021 trihydrochloride | GSK-3 |
Laduviglusib trihydrochloride; CT99021 trihydrochloride | ||
Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. | ||
M7455 | UK-5099 | Monocarboxylate Transporter (MCT) |
PF-1005023 | ||
UK-5099 (PF-1005023) is a potent inhibitor of the mitochondrial pyruvate carrier (MPC), it inhibits pyruvate-dependent O2 consumption with an IC50 of 50 nM. UK-5099 is also a cuproptosis inhibitor. | ||
M9678 | SAR407899 | ROCK |
SAR407899 is a potent and selective, ATP-competitive ROCK inhibitor with IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and rat ROCK-2, respectively. | ||
M9875 | ACT-389949 | FPR |
ACT389949 | ||
ACT-389949 is a first-in-class, potent, selective formyl peptide receptor 2/lipoprotein A4 receptor (FPR2)/(ALX) agonist with an EC50 value of 3 nM for FPR2/ALX entry into monocytes.Additionally, ACT-389949 is an excellent tool compound for in vitro and in vivo to further analyze FPR2-regulated activity, which could be used in the development of next-generation FPR signaling-regulated anti-inflammatory therapies. | ||
M10283 | AZD-5991 Racemate | Bcl-2 |
AZD-5991 Racemate is a Mcl-1 inhibitor with an IC50 of <3 nM in FRET assay. | ||
M10501 | PT2399 | HIF |
PT-2399 | ||
PT2399 is a potent and orally available antagonist of HIF-2 with an IC50 of 6 nM, PT2399 selectively disrupts the heterodimerization of HIF-2α with HIF-1β. | ||
M13405 | RIPK3-IN-1 | RIPK |
RIPK3-IN-1 is a RIPK3 TYPE II DFG-out inhibitor with IC50 of 9.1 nM. RIPK3-IN-1 inhibited ABL, BRAF/V599E, MAP4K3 and SRC with IC50 values of 0.37, 0.15, 0.012 and 0.075 μM, respectively. | ||
M13732 | SAR407899 hydrochloride | ROCK |
SAR407899 hydrochloride is a selective, potent and ATP-competitive ROCK inhibitor, with an IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and rat ROCK-2, respectively. | ||
M14117 | YKL-05-099 | Salt-inducible Kinase |
YKL-05-099 is a salt-inducible kinase (SIK) inhibitor. YKL-05-099 binds to SIK1 and SIK3 with IC50s of ~10 and ~30 nM, respectively. YKL-05-099 has slightly less potent SIK2-inhibitory (IC50=40 nM). | ||
M14133 | BMS-599626 Hydrochloride | EGFR/HER2 |
AC480 Hydrochloride | ||
BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. | ||
M14153 | Ravoxertinib hydrochloride | ERK |
GDC-0994 hydrochloride | ||
Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for ERK kinase activity with IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively. | ||
M14724 | LY 345899 | Dehydrogenase |
LY 345899 is a Folate analog and is a methylene tetrahydrofolate dehydrogenase (MTHFD1; DC301) and MTHFD2 inbhibitor with IC50 values of 96 nM and 663 nM, respectively and a Ki of 18 nM for MTHFD1. | ||
M14767 | SHIN1 | Transferase |
RZ-2994 | ||
SHIN1 (RZ-2994) is a human serine hydroxymethyltransferse 1 and 2 (SHMT1/2) inhibitor with IC50s of 5 and 13 nM, respectively, in an in vitro assay. | ||
M15108 | FR183998 free base | Na+/H+ Exchanger (NHE) |
FR183998 free base is a potent Na+/H+-exchange inhibitor, with IC50s of 0.3 nM, 3.1 nM and 6.5 nM by measurement of pHi change in rat lymphocytes, rat and human platelets, respectively. | ||
M20388 | AC480 (BMS-599626) | EGFR/HER2 |
AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. Phase 1. | ||
M20727 | BI 894999 | Epigenetic Reader Domain |
BI 894999 is a potent and selective BET inhibitor with IC50 of 5 nM and 41 nM for the binding of BRD4-BD1 and BRD4-BD2 to acetylated histones, respectively. BI 894999 is highly selective for BRD2/3/4 and BRDT (Kd of 0.49-1.6 nM), with at least a 200-fold selectivity vs. BRD4-BD1. | ||
M20791 | Amcinonide | NO Synthase |
Cyclocort, CL-34699 | ||
Amcinonide (Cyclocort, CL-34699) is an inhibitor of nitric oxide (NO) release from activated microglia with IC50 of 3.38 nM. | ||
M21035 | LCH-7749944 | PAK |
GNF-PF-2356 | ||
LCH-7749944 (GNF-PF-2356) is a novel and potent p21-activated kinase 4 (PAK4) inhibitor with an IC50 of 14.93 μM and has less potently inhibitory effect against PAK1, PAK5 and PAK6. LCH-7749944 causes successful inhibition of EGFR activity due to its inhibitory effect on PAK4. | ||
M21386 | Pelecopan | Complement System |
BCX9930 | ||
Pelecopan (BCX9930) is a potent, selective complement factor D inhibitor with oral activity and an IC50 value of 14.3 nM. | ||
M27808 | AZ12799734 | TGF-β Receptor |
AZ12799734 is a selective, orally active TGFBR1 kinase inhibitor with an IC50 of 47 nM. AZ12799734 is also a pan BMP and TGFβ inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.